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From the Clinic
C1q nephropathy in the setting of granulomatosis
with polyangiitis treated with tacrolimus
Granulomatosis with polyangiitis (GPA, formerly known as
Wegener’s granulomatosis) is a rare necrotizing vasculitis
of small and medium-sized blood vessels known to cause
inﬂammation of the respiratory tract (e.g. rhinitis, pul-
monary capillaritis) and kidney disease (ranging from
microhematuria to rapidly progressive glomerulonephritis)
[1]. More than 75% of patients with GPA eventually
develop renal involvement which can progress to end-
stage renal disease. The classic renal biopsy ﬁnding is
pauci-immune crescentic or segmental necrotizing glom-
erulonephritis [1].
We report here a 14-year-old male who presented with
a 3-week history of sinusitis, arthralgias, epistaxis, con-
junctivitis and a petechial rash over his lower extremities.
His laboratory workup was signiﬁcant for high titer cyto-
plasmic anti-neutrophil cytoplasmic antibodies (c-ANCA)
at 1:640; however, anti-proteinase 3 (PR3) and anti-
myeloperoxidase (MPO) antibodies were initially negative.
Serologic testing also revealed an elevated ESR at 35 mm/h
(35 mm/h), elevated CRP at 52.4 nmol/L (5.5 mg/L), and
an elevated rheumatoid factor at 36 kIU/L (36 IU/mL). His
initial serum creatinine was 61.88 µmol/L (0.7 mg/dL), and
his urinalysis showed hematuria with no leukocyturia
and no proteinuria (random urine protein/to/creatinine
ratio was 0.14). Plasma protein and serum albumin were
normal at 77 g/L (7.7 g/dL) and 41 g/L (4.1 g/dL), respect-
ively. He had a pulmonary nodule and right maxillary
sinus opaciﬁcation revealed by radiography. The patient
was diagnosed with GPA without signiﬁcant renal involve-
ment and was started on daily prednisone (0.5 mg/kg/
day) and weekly methotrexate (15 mg/m2/week). Monthly
cyclophosphamide infusions (750 mg/m2 per dose) were
initiated soon after due to the severity of the symptoms.
Despite 3 months of therapy, however, the patient suf-
fered from worsening arthritis, fatigue, cough, rash and
elevation in CRP to 187.6 nmol/L (19.7 mg/L). His prednis-
one dose was subsequently increased to 1 mg/kg/day. Six
months after the onset of symptoms, anti-PR3 antibodies
were positive. Concern grew for poor response to the
standard therapy given the persistent symptoms and wor-
sening serology despite treatment with steroids, metho-
trexate and cyclophosphamide for more than a year.
Fifteen months after the onset of symptoms, and 1 year
after the initiation of therapy, the patient experienced an
8 kg weight loss, fatigue, continued epistaxis and sinusitis,
and development of nephrotic-range proteinuria (3400
mg/day). Serum albumin remained normal at 44 g/L (4.4
g/dL). The serum creatinine mildly increased from 53
µmol/L (0.6 mg/dL) to 70.7 µmol/L (0.8 mg/dL). A kidney
biopsy was performed. Light microscopy revealed 16
glomeruli, with 5 showing segmental sclerosis; 3, global
sclerosis; and 1, ﬁbrous crescent (Figure 1A). Immuno-
ﬂuorescence (IF) showed comma-shaped C1q and trace
granular IgG deposits in the glomeruli, as well as C3 de-
position in the blood vessels (Figure 1B). Electron micros-
copy (EM) demonstrated focal foot process effacement as
well as focal subendothelial and paramesangial electron
dense deposits. Based on these biopsy ﬁndings, the
patient was diagnosed with C1q nephropathy (C1qN).
Given the lack of clinical response to the original therapy,
prednisone, methotrexate and cyclophosphamide were
discontinued and tacrolimus was started at 1 mg twice
daily. Plasmapheresis and rituximab were considered as
therapeutic options; however, due to the patient’s good
response to tacrolimus, these treatments were not per-
formed. A month later, lisinopril was initiated to treat the
patient’s hypertension.
The patient has been followed for 2 years since diagno-
sis. After initiation of tacrolimus, an improvement in his
pulmonary, musculoskeletal and ophthalmic symptoms
was observed. His proteinuria decreased from a peak of
3389 to 598 mg/day (Figure 1C); the c-ANCA titer de-
creased from a peak of 1:640 to 1:320; and the anti-PR3
antibody titer decreased from a peak of 72 to 62 units.
C1qN was originally deﬁned by Jeanette and Hipp as a
disease process characterized by nephrotic-range protein-
uria, with kidney biopsy ﬁndings demonstrating dominant
C1q staining in a predominantly mesangial pattern on IF
[2]. The glomeruli may show minimal abnormalities, focal
segmental glomerulosclerosis or mesangial proliferation.
Widespread effacement of the podocyte foot processes
can also be seen on EM. Exclusion criteria for C1qN include
evidence of systemic lupus erythematosus, IgA nephropa-
thy or membranoproliferative glomerulonephritis type I [2].
Clinical manifestations can range from relatively benign
cases of isolated hematuria or proteinuria to severe cases
of nephrotic syndrome, nephritic syndrome or a combin-
ation of the two [2]. Very few cases of ANCA-associated
vasculitis with C1qN have been reported to date [3, 4], and
to our knowledge, C1qN has not been reported speciﬁcally
in association with anti-PR3-positive GPA. In our patient, we
postulate that B-cell activation may have resulted in glom-
erular immunoglobulin deposition, allowing for binding of
C1q to the Fc portion of the IgG antibodies. This case may
also represent two concurrent rare diseases in one individ-
ual without a causal relationship. Since the overall patho-
genesis of C1qN remains incompletely understood, the
exact mechanism by which the patient developed C1qN in
the background of GPA remains unknown.
According to recent case series reports, most patients
with C1qN and steroid-resistant nephrotic syndrome
achieved remission with the addition of a calcineurin in-
hibitor, e.g. cyclosporine or tacrolimus [5]. We hypothesize
that in our patient with GPA and C1qN resistant to con-
ventional therapy, treatment with tacrolimus resulted in
systemic immunomodulation leading to a decrease in the
intensity of the symptoms of systemic autoimmune disease,
as well as reduction of proteinuria. Lisinopril likely further as-
sisted in the resolution of proteinuria.
This is the ﬁrst case to our knowledge of a patient with
C1qN associated with GPA, who demonstrated dramatic
improvement of his nephrotic-range proteinuria and
extra-renal symptoms with tacrolimus. While this repre-
sents a rare case of C1qN in the setting of GPA, consider-
ation should be given to this entity in patients with
refractory GPA and proteinuria, as these manifestations
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could portend a worse prognosis. Moreover, this report
suggests that tacrolimus could be considered as a thera-
peutic option in such cases.
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Fig. 1. Renal histological ﬁndings and response to treatment with tacrolimus and lisinopril. (A) Light microscopy shows focal segmental and global
glomerulosclerosis along with varying degrees of interstitial inﬂammatory inﬁltrate and ﬁbrosis. Arrow points to segmentally sclerosed glomerulus
(hematoxylin and eosin stain ×100). (B) Immunoﬂuorescence shows glomerular and mesangial C1q deposits with the classic ‘comma-shaped’
morphology (white arrows). (C) Proteinuria worsened despite treatment with prednisone, methotrexate and cyclophosphamide for over a year. Initiation
of tacrolimus and lisinopril resulted in rapid improvement of proteinuria. The decrease in urine protein was also accompanied by a decrease in the severity
of systemic GPA symptoms.
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